Obesity trials in Taiwan
44 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Where
- Changhua, Chiayi City, Kaohsiung City, Taichung, Tainan, Taipei
- Age
- 18 years and over
- People
- 2,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351045 · EU 2025-523104-71-00 - Phase 3Taking peopleA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Where
- Changhua, Chiayi City, Kaohsiung City, Taichung, Tainan, Taipei
- Age
- 18 years and over
- People
- 1,600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07351058 · EU 2025-523106-32-00 - Phase 3Taking peopleA Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Where
- Kaohsiung City, Taichung, Tainan, Taipei
- Age
- 18 years and over
- People
- 2,001 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07794579 · EU 2026-526175-35-00 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Where
- Kaohsiung City, Kaohsiung Niao Sung Dist, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 1,035 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07282600 · EU 2025-523658-15-00 - Phase 3Taking peopleEfficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Where
- Changhua County, Kaohsiung Niao Sung Dist, Taichung, Tainan, Taipei
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07353931 · EU 2025-523768-19-00 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Where
- Taichung, Tainan, Taoyuan
- Age
- 18 years and over
- People
- 800 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07369011 · EU 2025-523769-11-00 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Where
- Chiayi City, Kaohsiung City, Kaohsiung Niao Sung Dist, Taichung, Tainan, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07392190 · EU 2025-523659-73-00 - Phase 3Taking peopleEfficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
- Where
- Tainan, Taipei, Taoyuan City
- Age
- 6 years to 11 years
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07817875 · EU 2025-522020-27-00 - Phase 3Taking peopleA Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Where
- Hsinchu
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07881458 · EU 2026-527230-31-00 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Where
- Changhua, Chiayi City, Kaohsiung City, New Taipei City, Taichung, Tainan, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 2,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00 - Phase 3Taking peopleMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Where
- Kaohsiung City, Taichung, Tainan, Taipei
- Age
- 18 years to 99 years
- People
- 5,056 worldwide
- Run by
- Amgen
See details and how to joinNCT07037459 - Phase 3Taking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Where
- Changhua, Kaohsiung City, Taichung, Tainan, Taipei, Zhubei
- Age
- 18 years and over
- People
- 1,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784270 - Phase 3Taking peopleA Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
- Where
- Changhua, Kaohsiung City, Taichung, Tainan, Tainan County, Taipei
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07667803 - Phase 3Taking peopleAMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Where
- Chiayi City, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07571109 · EU 2024-520443-16-00 - Phase 3Taking peopleA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Where
- Kaohsiung City, Taichung, Taipei, Taoyuan
- Age
- 8 years to 18 years
- People
- 460 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07253285 · EU 2023-509176-42-00 - Phase 3Taking peopleA Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- Where
- Taichung, Tainan, Taipei, Taoyuan
- Age
- 12 years to 17 years
- People
- 300 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06439277 - Phase 3Taking peopleA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Where
- Chiayi City, Kaohsiung City, Kaohsiung Niao Sung Dist, Taipei
- Age
- 18 years and over
- People
- 1,980 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07321886 · EU 2025-523657-34-00 - No phaseTaking peopleMetabolic Syndrome and Prediabetes
- Where
- Taipei
- Age
- 18 years and over
- People
- 2,000
- Run by
- National Taiwan University Hospital
See details and how to joinNCT07243821 - No phaseTaking peopleA Wearable Device and AI-Supported Diet and Exercise Intervention
- Where
- Taipei
- Age
- 20 years and over
- People
- 120
- Run by
- National Taiwan University Hospital
See details and how to joinNCT06630663 - No phaseEnrolling by invitationA Prospective Cohort Study on Patient With Obesity Undergoing Weight Change
- Where
- Taipei
- Age
- 18 years and over
- People
- 500
- Run by
- National Taiwan University Hospital
See details and how to joinNCT07239167 - No phaseTaking peoplePatients With Type 2 Diabetes
- Where
- Taipei
- Age
- 18 years and over
- People
- 2,000
- Run by
- National Taiwan University Hospital
See details and how to joinNCT07245082 - Phase 3Taking peopleAMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Where
- Chiayi City, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07571005 · EU 2024-520442-36-00 - No phaseTaking peopleMulti-Modal Digital Interventions for Adolescent Weight Management
- Where
- Hsinchu, Taipei
- Age
- 12 years to 18 years
- People
- 200
- Run by
- National Yang Ming Chiao Tung University
See details and how to joinNCT06920862 - No phaseNot yet taking people in TaiwanGenerative AI-Based Health Education for Older Adults With Sarcopenic Obesity
- Where
- Taipei
- Age
- 50 years to 99 years
- People
- 500
- Run by
- Taipei Medical University
See details and how to joinNCT07782320 - Phase 3Taking peopleA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Where
- Kaohsiung City, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 5,610 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07567001 · EU 2025-523717-29-00